FDA Approves New RSV Treatment for Infants

FDA approves new RSV treatment for infants

The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday.

New therapy approved for RSV in kids - WCCB Charlotte's CW

WASHINGTON – The Food and Drug Administration has approved a new monoclonal antibody to protect infants from RSV. The infection is the top cause of infant hospitalization in the U.S. and can be fatal. The therapy, Enflonsia, is made by Merck. It’s given a single 105-milligram shot to protect newborns and infants from RSV through their first virus season. In a mid-to-late stage trial, it reduced RSV associated hospitalizations in infants by more …

Which ASX company has just secured FDA approval?

FDA Approves Clesrovimab to Prevent RSV in Infants During First Season

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention

Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.